Montreal Heart Institute, Montréal, Québec, Canada.
Center for Genomic Medicine and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
PLoS Genet. 2023 Mar 16;19(3):e1010680. doi: 10.1371/journal.pgen.1010680. eCollection 2023 Mar.
Genome-wide association studies have identified >250 genetic variants associated with coronary artery disease (CAD), but the causal variants, genes and molecular mechanisms remain unknown at most loci. We performed pooled CRISPR screens to test the impact of sequences at or near CAD-associated genetic variants on vascular endothelial cell functions. Using CRISPR knockout, inhibition and activation, we targeted 1998 variants at 83 CAD loci to assess their effect on three adhesion proteins (E-selectin, ICAM1, VCAM1) and three key endothelial functions (nitric oxide and reactive oxygen species production, calcium signalling). At a false discovery rate ≤10%, we identified significant CRISPR perturbations near 42 variants located within 26 CAD loci. We used base editing to validate a putative causal variant in the promoter of the FES gene. Although a few of the loci include genes previously characterized in endothelial cells (e.g. AIDA, ARHGEF26, ADAMTS7), most are implicated in endothelial dysfunction for the first time. Detailed characterization of one of these new loci implicated the RNA helicase DHX38 in vascular endothelial cell senescence. While promising, our results also highlighted several limitations in using CRISPR perturbations to functionally dissect GWAS loci, including an unknown false negative rate and potential off-target effects.
全基因组关联研究已经确定了 >250 个与冠状动脉疾病 (CAD) 相关的遗传变异,但大多数位点的因果变异、基因和分子机制仍然未知。我们进行了 pooled CRISPR 筛选,以测试 CAD 相关遗传变异处或附近的序列对血管内皮细胞功能的影响。我们使用 CRISPR 敲除、抑制和激活,靶向 83 个 CAD 位点的 1998 个变体,以评估它们对三种粘附蛋白(E-选择素、ICAM1、VCAM1)和三种关键内皮功能(一氧化氮和活性氧产生、钙信号)的影响。在错误发现率≤10%时,我们在位于 26 个 CAD 位点内的 42 个变体附近鉴定出具有显著 CRISPR 干扰的变体。我们使用碱基编辑来验证 FES 基因启动子中的一个假定因果变体。尽管一些位点包括以前在内皮细胞中表征的基因(例如 AIDA、ARHGEF26、ADAMTS7),但大多数基因首次被认为与内皮功能障碍有关。对其中一个新位点的详细特征分析表明,RNA 解旋酶 DHX38 参与了血管内皮细胞衰老。虽然很有前景,但我们的结果也突出了使用 CRISPR 干扰来功能解析 GWAS 位点的几个局限性,包括未知的假阴性率和潜在的脱靶效应。